OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundance

By afschroeder • January 28, 2026

Bernard MJ, Gallardo A, Ruiz A, Diaz JA, Nunley NM, Dove RN, Zhang S, Lee E, Heering KY, Varuzhanyan G, Bopardikar S, Hashimoto T, Agrawal R, Smith CM, Wilde BR, Matulionis N, Richards HM, Lee SCS, Sharifi MN, Lang JM, Zhao SG, Witte ON, Haffner MC, Shackelford DB, Boutros PC, Christofk HR, Goldstein AS. OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundance. Mol Cancer Res. 2026 Jan 27. doi: 10.1158/1541-7786.MCR-25-0913. Epub ahead of print. PMID: 41591383.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Eosinophilic cholangitis as an indeterminate biliary mimic: A systematic review of outcomes

Stirrat T, Wilkey M, Ransibrahmanakul V, Singh L, Allen O, Kanth P, Rangnekar A, Redfield R. Eosinophilic cholangitis as an indeterminate biliary mimic: A systematic[...]

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer

Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes[...]

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial

Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie[...]